Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Idera Pharmaceuticals has received patents covering compositions and methods of using its synthetic immune modulatory oligonucleotides targeted to Toll-like receptors (TLRs).
Subscribe to our email newsletter
In addition to the recently issued US patents, the company was granted: AU 2004241093, corresponding to US Patent No 7,569,554, entitled ‘Synergistic Treatment of Cancer Using Immunomers in Conjunction with Therapeutic Agents;’ AU 2005222909.
Additionally, it has also received AU 2005222909 corresponding to US Patent Application No 11/078,654, entitled ‘Enhanced Activity of HIV Vaccine Using a Second Generation Immunomodulatory Oligonucleotide;’ JP 4443810, corresponding to US Patent No 6,815,429, entitled ‘Modulation of Oligonucleotide CpG-Mediated Immune Stimulation by Positional Modification of Nucleosides,’ and MK 903127, corresponding to US Patent Application No 11/153,054, entitled ‘Immunostimulatory Oligonucleotide Multimers.’
Idera Pharma’s intellectual property portfolio currently contains over 500 patents and patent applications worldwide and includes claims for TLR-targeted compounds, antisense chemistry, and oral delivery of certain oligonucleotides.